Contact SCGE




Gene Therapy Trial Report

Summary

A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.


NCTID NCT05454566 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Osteoarthritis, Knee
Disease Ontology Term DOID:8398
Compound Name ICM-203
Compound Description hNkx3.2-D2 CDS
Sponsor ICM Co. Ltd.
Funder Type Industry
Recruitment Status
Not yet recruiting
Enrollment Count 18 (ESTIMATED)
Results Posted Not Available

Therapy Information


Target Gene/Variant NKX3-2
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intraarticular
Drug Product Type Viral vector
Delivery System Viral transduction
Vector Type AAV5.2
Editor Type none
Dose 1 6E12 vg
Dose 2 2E13 vg
Dose 3 6E13 vg

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2022-07-04
Completion Date 2027-11
Last Update 2025-05-01

Participation Criteria


Eligible Age 50 Years - 80 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL
Eligibility Criteria
Inclusion Criteria: 1. Body mass index (BMI) of 18.0 to 40.0 kg/m2, inclusive, at the time of screening. 2. Kellgren-Lawrence grade 2 or grade 3 OA of target knee. 3. Target knee pain between 4 and 9, inclusive, on an NRS ranging from 0 (no pain) to 10 (worst pain imaginable), at the time of screening. 4. KOOS function in daily living score \>25, a measure of knee function ranging from 0 (extreme problems) to 100 (no problems), at the time of screening . 5. A stable treatment regimen for symptomatic relief of OA, including NSAIDs, for 4 weeks prior to screening. Exclusion Criteria: 1. History of rheumatoid arthritis, psoriatic arthritis, gout, pseudogout, autoimmune OA, chondrocalcinosis, hemochromatosis, villonodular synovitis, and synovial chondromatosis or other disorder that in the opinion of the Investigator could cause inflammation of the knee. 2. Injection of steroid, hyaluronate or other agent, into the target knee less than 90 days prior to day 1. 3. Major injury to the target knee, such as torn ligament or severe sprain, within 12 months of screening. 4. Disability so severe that the subject cannot comply with the study requirements, including knee symptoms that result in significant difficulty or inability to walk. 5. Surgery on the target knee within 180 days prior to day 1. 6. Total knee arthroplasty or other knee surgery planned in the next 12 months. 7. Active joint infection or other concurrent medical or psychiatric condition that, in the opinion of the Investigator, would make the subject unsuitable for the study.
View Inclusion and Exclusion Criteria at ClinicalTrials.gov

Locations


No.of Trial Sites
Locations

Regulatory Information


Has US IND True
FDA Designations
Recent Updates Update on Phase 1/2a study given at ASGCT 2024

Resources/Links